Biotech Values

[Rocky3]

so why post that superfluous chart?

I surely don't consider it superfluous.

Very interesting in many ways.

Second quarter revenue for MNTA should be strong (already known from raw script numbers).

Strong growth in total scripts (both Lov and mEn) from mEn launch.

But decline in total scripts in June from May (even after considering holiday).

Last item brings up competitive issues and longer term concerns. But will need to see future numbers for more clarity. Second quarter conference calls may provide additional info.